.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The MiG randomized trial compared metformin with insulin in women with gestational diabetes requiring pharmacologic treatment. Composite neonatal outcomes were not significantly different between groups, and many women preferred metformin because of its oral administration. However, a substantial proportion required supplemental insulin to achieve glycemic targets. For obstetricians and physicians, the study is useful because it frames metformin as one option rather than a universal replacement for insulin. Placental transfer, long-term offspring evidence, maternal preferences and local guidelines should be considered. Nutrition therapy, glucose monitoring and appropriate fetal surveillance remain essential regardless of medication choice. The practical message is that pharmacologic treatment should be individualized, with clear thresholds for escalation when glycemic control is inadequate. The trial also highlights the importance of shared decision-making in pregnancy, where convenience and patient acceptability need to be balanced against the evolving evidence base.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The MiG randomized trial compared metformin with insulin in women with gestational diabetes requiring pharmacologic treatment. Composite neonatal outcomes were not significantly different between groups, and many women preferred metformin because of its oral administration. However, a substantial proportion required supplemental insulin to achieve glycemic targets. For obstetricians and physicians, the study is useful because it frames metformin as one option rather than a universal replacement for insulin. Placental transfer, long-term offspring evidence, maternal preferences and local guidelines should be considered. Nutrition therapy, glucose monitoring and appropriate fetal surveillance remain essential regardless of medication choice. The practical message is that pharmacologic treatment should be individualized, with clear thresholds for escalation when glycemic control is inadequate. The trial also highlights the importance of shared decision-making in pregnancy, where convenience and patient acceptability need to be balanced against the evolving evidence base.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
